Viewing Study NCT06504719



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06504719
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: None
First Post: 2024-04-09

Brief Title: Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Sponsor: None
Organization: None

Study Overview

Official Title: Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients With Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The study aims to evaluate real-world efficacy and toxicity data of treatment with Trastuzumab deruxtecan T-DXd a HER2-targeting ADC and sacituzumab govitecan SG a TROP-2-targeting ADC in pretreated patients with advanced breast cancer
Detailed Description: Antibody-drug conjugates ADCs have significantly changed the therapeutic landscape of advanced breast cancer Trastuzumab deruxtecan T-DXd a HER2-targeting ADC and sacituzumab govitecan SG a TROP-2-targeting ADC recently demonstrated superior efficacy over standard of care treatments depending on breast cancer subtype The study aims to evaluate real-world efficacy and toxicity data of treatment with T-DXd and SG in pretreated patients with advanced breast cancer

This study includes a retrospectiveprospective multicenter review of medical records of patients with advanced breast cancer who received treatment with T-DXd and SG at Departments of Oncology affiliated with the Hellenic Cooperative Oncology Group HeCOG

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None